Bibliography
- Norman P. Kinase inhibitor pipelines, CHI insight pharma reports December 2007
- Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009;228(1):149-69
- Denyer J, Patel V. Syk kinase inhibitors in allergic diseases. Drug News Perspect 2009;22(3):146-50
- Lusková P, Dráber P. Modulation of the Fcepsilon receptor I signaling by tyrosine kinase inhibitors: search for therapeutic targets of inflammatory and allergy diseases. Curr Pharm Des 2004;10(15):1727-37
- Yamamoto N, Takeshita K, Shichijo M, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 2003;306(3):1174-81
- Hirabayashi A, Mukaiyama H, Kobayashi H, et al. A novel Syk family kinase inhibitor: design, synthesis, and structure-activity relationship of 1,2,4-triazolo[4,3-c]pyrimidine and 1,2,4-triazolo[1,5-c]pyrimidine derivatives. Bioorg Med Chem 2008;16(15):7347-57
- Cywin CL, Zhao BP, McNeil DW, et al. Discovery and SAR of novel Naphthyridines as potent inhibitors of spleen tyrosine kinase (SYK). Bioorg Med Chem Lett 2003;13(8):1415-8
- Rossi AB, Herlaar E, Braselmann S, et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol 2006;118(3):749-55
- Bajpai M. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009;12(3):174-85
- Rigel Pharmaceuticals, Inc., 2,4-Pyrimidinediamine Compounds And Their Uses. WO03063794; 2003
- Available from: http://www.rigel.com /rigel/aa
- A study to assess the effect Of PF-03526299 on lung function following an allergen challenge in asthmatic subjects NCT00877539. Available from: http://clinicaltrials.gov
- Vipul Patel at Inflammation 2009, 14 May 2009